These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27637937)

  • 1. MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice.
    Brostoff T; Pesavento PA; Barker CM; Kenney JL; Dietrich EA; Duggal NK; Bosco-Lauth AM; Brault AC
    Vaccine; 2016 Oct; 34(44):5366-5375. PubMed ID: 27637937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
    Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
    J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.
    Maximova OA; Speicher JM; Skinner JR; Murphy BR; St Claire MC; Ragland DR; Herbert RL; Pare DR; Moore RM; Pletnev AG
    Vaccine; 2014 May; 32(26):3187-97. PubMed ID: 24736001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice.
    Venter M; van Vuren PJ; Mentoor J; Paweska J; Williams J
    Vaccine; 2013 Aug; 31(37):3856-62. PubMed ID: 23820079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
    Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations.
    Yu L; Robert Putnak J; Pletnev AG; Markoff L
    Vaccine; 2008 Nov; 26(47):5981-8. PubMed ID: 18805457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations.
    Schlick P; Kofler RM; Schittl B; Taucher C; Nagy E; Meinke A; Mandl CW
    Vaccine; 2010 Aug; 28(36):5903-9. PubMed ID: 20600500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to an attenuated West Nile virus NS4B-P38G mutant strain.
    Welte T; Xie G; Wicker JA; Whiteman MC; Li L; Rachamallu A; Barrett A; Wang T
    Vaccine; 2011 Jun; 29(29-30):4853-61. PubMed ID: 21549792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
    Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
    J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.
    Hughes HR; Crill WD; Davis BS; Chang GJ
    Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vector derived artificial miRNA mediated inhibition of West Nile virus replication and protein expression.
    Karothia D; Kumar Dash P; Parida M; Bhagyawant SS; Kumar JS
    Gene; 2020 Mar; 729():144300. PubMed ID: 31884102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection.
    Chang GJ; Davis BS; Stringfield C; Lutz C
    Vaccine; 2007 Mar; 25(12):2325-30. PubMed ID: 17224209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.